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Summary Inherent or acquired resistance to multiple natural product drugs in human tumour cells is often associated with increased
expression of multidrug resistance protein (MRP), a 190-kDa integral membrane protein that belongs to the ATP-binding cassette (ABC)
superfamily of transport proteins. Both clinical and experimental investigations of MRP have been facilitated by several monoclonal antibodies
(MAbs) generated against intracellular epitopes of the molecule. Recently, however, several new ABC transporters that are quite closely
related to MRP have been identified, raising concems about the specificity of the MRP-reactive MAbs. In the present study, we have mapped
the epitopes of MAbs MRPr1 and MRPm6 to the decapeptides 23GSDLWSLNKE247 (located in the intracellular loop between the first and
second membrane-spanning domains of MRP) and 1511PSDLLQQRGL'1 (located nearthe carboxy terminus of MRP) respectively. Alignment
of the MRPr1 and MRPm6 epitope sequences with the comparable regions in mammalian ABC proteins most closely related to MRP
indicates that, with the exception of munne mrp, the sequences are poorly conserved. We conclude that MAbs MRPm6 and MRPr1, together
with MAb QCRL-1, which has previously been mapped to the heptapeptide 918SSYSGDI924, remain highly specific probes for detection of
different regions of the MRP molecule.
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Successful treatment of manv human tumours is often limited bv
the development of druc resistance. Experimentally, resistance to
natural product drugs may be conferred by overexpression of one
or other of the integral membrane proteins. MRP or P-glyco-
protein. both of which are members of the ATP-binding cassette
(ABC) superfamily of transport proteins (Deeley and Cole. 1997).
ABC transporters typically consist of a hydrophrobic polytopic
membrane-spanning domain (MSD) followed by a cytosolic
nucleotide-binding domain (NBD) that contains three signature
motifs (Higins. 1992). Many eukarvotic ABC proteins. includine
the 190-kDa MRP and 170-kDa P-glycoprotein. contain two
MSDs and tw-o NBDs organized in a tandemly duplicated fashion.
However. unlike P-glycoprotemi. MRP and several other closelv
related proteins contain an additional NHW-proximal MSD (Cole et
al. 1992: Bakos et al. 1996: Loe et al. 1996a: Deelev and Cole.
1997: Stride et al. 1996). We haxe recently shoun bv site-directed
mutag,enesis of N-glycosylation sites that. in MRP. this MSD
contains an odd number oftransmembrane helices and. in contrast
to P-glycoprotein. the amino-terminus of MRP is extracytosolic
(Hipfner et al. 1997).
Whereas both NRP and P-glycoprotein confer resistance to
chemotherapeutic agents such as doxorubicin and xincristine bv
reducing cellular accumulation of these drugs. MRP has also been
demonstrated to be a prmary active transporter of several struc-
turally diverse conjugated organic anions. Known high-affinity
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substrates include the cvsteinvl leukotriene (LT) C4. 17-oestradiol
17-(D-glucuronide) and glutathione conjugates of activated afla-
toxin (Leier et al. 1994: Muller et al. 1994: Loe et al. 1996b. c.
1997). However. conjugation is not known to play an important role
in the metabolism of most of the drugs included in the MRP resis-
tance phenotype. and it has not been possible to demonstrate active
transport of unconjugated substrates in vitro (Muller et al. 1994:
Jedlitschkv et al. 1996: Loe et al. 1996b). although we and others
have demonstrated that MRP-mediated ATP-dependent transport of
vincristine and aflatoxin B, can occur in the presence of reduced
glutathione (Loe et al. 1996b. 1997: Bamouin et al. 1997).
Numerous studies generally support the notion that P-glycopro-
tein plays a role in the druc resistance observed in several human
malignancies (Filipits et al. 1996b). Although studied to a lesser
extent. MRP also appears to be clinically important in a number
of haematological and solid tumours. including neuroblastoma.
certain instances of drug resistant retinoblastoma. some subtypes
of non-small-cell lunc cancer and breast cancer (Ota et al. 1995:
Filipits et al. 1996a: Giaccone et al. 1996: Norris et al. 1996: Chan
et al. 1997: Nooter et al. 1997).
To facilitate both experimental and clinical studies of MRP.
several MRP-reactive monoclonal antibodies (MAbs) have been
generated (Fliens et al. 1994. 1996: Hipfner et al. 1994). However.
the epitope ofonly one of these. MAb QCRL-1. has been mapped
to single amino acid resolution (Hipfner et al. 1996). MAb QCRL-
1 was raised against membranes from H69AR drua-resistant lungy
cancer cells. which express high levels of MRP. We have previ-
ously determined that the critical core of its epitope is the
heptapeptide (918SSYSGDI94) located in the cytosolic region
linking, the first NBD to the third MSD ofthe MRP molecule. Tw-o
other MRP-reactive MAbs. namelI. rat MAb MRPrl and munrne
MAb MRPm6. Aere raised against fusion proteins. one containing
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Figure 1 Immunodot blots of membrane proteins prepared from Sf21 insect
cells infected with MRP deletion constructs MRPZ9- 153, and MRPe t.
Crude membranes were prepared and Sf21/MRP229-1531 (1 j9) and
Sf21/MRP',, (3 jg) membrane proteins were blotted in duplicate onto
Immobilon-P membrane. The membrane was probed with MRP-reactive
antibodies, MRP-1 potyconal antiserum (top) and MAb MRPrl (bottom). AJl
four frames in the figure are from the same film exposure
a 167 anino acid peptide from the amino-proximal region of
human MRP and the other containing a discontinuous 172 amino
acid peptide from the carboxy-proximal region of the protein
(FHens et al. 1994). Like MAb QCRL-1. these MAbs recognize
linear intracellular epitopes ofMRP and have been very useful for
protein characterization and subcellular localization. as well as for
immunohistochemical detection of MRP in normal and malianant
cells and tissues (Filipits et al. 1996a; Flens et al 1996: Nooter et
al. 1995). In the present study. we have determined that the epitope
sequences of MAbs MRPrl and MRPm6 are localized to amino
acids 238-247. located in the intracellular loop between the first
and second MSDs of MRP. and amino acids 1511-1520. located
carboxy-proximal to the second NBD of MRP very near to the
carboxy terminus ofthe protein respectivelx.
MATERIALS AND METHODS
Antibodies
Rat MAb MRPrl (lgG and mouse MAb MRPm6 (IgG ) were
raised against maltose-binding protein fusion proteins containing
human MRP amino acids 194-360 and human MRP amino acids
1294-1430 plus 1497-1531 respectively (Flens et al. 1994).
Mouse MAb QCRL-1 (Centocor Diagnostics. Malvem. PA. USA)
was raised against cell membranes from MRP-overexpressinc
H69AR cells (Mirski et al. 1987) and has been shown to bind to
the heptapeptide 911SSYSGD19'4 in the connector region of human
MRP (Hipfner et al. 1994. 1996). MRP-1 and MRP-2 are rabbit
polvclonal antisera raised against two 15 amino acid peptides
containina the actixe transport' family signature sequences from
the first and second NBDs of MRP (amino acids 765-779 and
1427-1441 respectively) (Hipfner et al. 1996. 1997).
Generation of constructs, production of recombinant
baculovirus and viral infection
Two constructs encodinc MRP molecules with NWH,-terminal dele-
tions were prepared and transferred into the recombinant donor
plasmid pFASTBAC1 (Life Technologies. Burlington. Ontario.
Canada) as described elsewhere (Gao et al. 1998). These
constructs. designated Sf21/MRP,>, and Sf21/MRP, ,
encode amino acids 229-1531 and 281-1531 ofMRPrespectively.
The only amino acid introduced during construction of both
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Figure 2 Immunoblots of formic acid digests of H69AR cell membrane
proteins with MRP-reactive antibodies. Membrane proteins were prepared
from H69AR cells, hydrolysed with formic acid and the resuftant polypeptides
(20 gg per lane) were resolved by SDS-PAGE on Tns-Tricine gels followed by
transfer to lmmobilon-P membrane. Duplicate lanes were probed with MRP-2
po4yclonal antiserum (left) and MAb MRPm6 (right). The positions of
molecular mass markers are indicated between the two panels. The box
diagram of MRP below the blots shows the approximate limits of the three
membrane-spanning domains (MSDs) (shaded black), and the two
nucleotide-binding domains (NBD) (shaded grey). The positions of the eight
predicted formic acid cleavage sites are indicated, as is the location of the
MRP formic acid fragmrent of approximately 16 kDa detected in the
immunob4ots above
Xectors was an initiator methionine residue. Recombinant bacmids
and baculovirus of Sf2I/MRP.2,1 l and SF21/MRP,,1-l, were
produced and used to infect Spodoptera frugiperda Sf21 cells as
previously described (Gao et al. 1996).
Preparation of membrane protein dot blots
Cells were harvested and membrane-enriched fractions were
prepared as described (Hipfner et al. 1994: Gao et al. 1996).
Membrane proteins in Tris-buffered saline (TBS) (10 num
Tris-0.15 m. sodium chloride. pH 7.5) were blotted onto
Immobilon-P polvvinvlidene fluoride membrane (PVDF)
(Millipore. Mississauga. Ontario. Canada) using a 96-well vacuum
manifold. After washinc with TBS/0.05%c Tween-20 (TBS-T). the
blots were cut into strips. transferred to a 24-slot incubation trav
and immunoblotted as described below.
Formic acid hydrolysis of MRP
Cell membrane-enriched fractions were prepared from MRP-over-
expressing H69AR cells. Crude membrane protein (200 Ag) was
pelleted by centrifugation at 100 000g and resuspended in 100gl
of 70% formic acid. After incubation at 37C for 48 h. the sample
was lvophilized. and the pellet was washed by resuspension in
distilled water followed by lyophihzation. The final pellet was
resuspended in Tricine sample buffer (BioRad. Hercules. CA.
USA) and heated for 45 min at 40'C. Polypeptides were separated
on a 16.5% Tris-Tricine gel. transferred to PVDF and immuno-
blotted as descnrbed below.
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Figure 3 Epitope mapping by immunoblotting of overlpping peptides. Peptides were synthesized in spots in a 96-weJl format on a stable inert mnembrane. The
numbers on the bkot indicate the location of the peptide spots, and the positons of the corresponding MRP amino acid sequences of the peptides are indicated
to the lefL The sequence of the most reactive peptide is also indicated on each blot (A) A blot of 11 overlapping decapeptides spanning MRP amino acids
228-287 probed with MAb MRPrl. (B) A blot of 46 overlapping nona- and decapeptides spanning MRP amino acids 1388-1531 probed with MAb MRPm6
Immunoblotting
Blots were blocked for at least 1 h in 4% skim milk powder in
TBS-T. incubated with pnrmary antibody (MAb MRPrl. MAb
MRPrn6. MAb QCRL-1. MRP-1 or MRP-2 polyclonal antisera)
diluted in blocking solution for 1-18 h and then processed as
previously described (Hipfner et al. 1994). Primary antibody
binding was visualized by enhanced chemiluminescence detection
(Boehringer Mannheim. Laval. Quebec. Canada) using, horse-
radish peroxidase-conjugated F(ab'), fragments of goat anti-rat
IgG (H+L. for MAb MRPrl ). goat anti-mouse IgG+IgM (H+L. for
MAbs MRPm6 and QCRL-1. Pierce. Professional Diagnostics.
Edmonton. Alberta. Canada) or goat anti-rabbit IgG (H+L. for
antisera MRP-I and MRP-2. Jackson ImmunoResearch. West
Grove. PA. USA).
Synthesis and immunoblotting of immobilized peptides
Immobilized peptides were synthesized by Research Genetics
(Huntsville. AL. USA) using the peptides on paper technique.
Briefly. peptides were synthesized in nanomolar quantities in a
96-well format. using standard Fmoc chemistry. directly on the
surface ofan inert membrane. The peptides were covalently linked
to the membrane by their COOH-terminal ends via a 6-amino-
hexanoic acid spacer. For mapping the MAb MRPm6 epitope. 45
decapeptides and one nonapeptide spanning MRP amino acids
1388-1531 and overlapping by seven amino acids [i.e. each
successive peptide contained the last seven residues of the
preceding peptide plus the next three amino acids in the sequence
(or the next two in the case ofthe nonapeptide)] were synthesized.
For mapping the MAb MRPrl epitope. 11 decapeptides spanning
MRP amino acids 228-287 and overlapping by five residues were
synthesized. The membranes were immunoblotted with MAb
MRPm6 or MAb MRPrl essentially as described above. except
that 1%c bovine serum albumin/2% skim milk powder in TBS-T
was used as the blocking solution. MAbs MRPm6 and MAb
MRPrl were used at concentrations of 2 ng ml' and 0.5 ng ml-I
respectively.
Peptide competition of MAb binding
The ability of two peptides (single-letter amino acid code. GSDL-
WSLNKE and PSDLLQQRGL) (Research Genetics) to inhibit
binding of MAbs to MRP was tested by competitive immunoblot-
ting. Crude membrane proteins (5 jg per lane) prepared from
human MRP-transfected HEK cells (HEK4.Rp) (Stride et al. 1997)
were separated by SDS-PAGE and transferred to PVDF
membrane. The membrane was cut into strips and blocked as
above. MAbs MRPrl. MRPm6 and QCRL-1 (4 ng ml-) were
mixed with increasing concentrations of peptide GSDLWSLNKE
(0-200 ng ml-) or peptide PSDLLQQRGL (0-100 gg ml) in 1.5
ml of TBS-T containing 0.1% BSA and 0.005% sodium azide.
After incubation for45 mim at room temperature. the MAb/peptide
mixtures were added to the strips. incubated overmight at room
temperature and the strips processed as above.
RESULTS
Localization of the MAb MRPrl epitope
The approximate location of the MAb MRPrl epitope was deter-
mined by immunodot blot analysis of membranes prepared from
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Figure 4 Peptidecompetiton of MAb MRPrl and MRPm6 binding.
Membrane proteins fromnHEK.P cells (5 igg perlane) were separated by
SDS-PAGE and transferred to PVDF. The blot was cut into strips
corresponding tosingle Lanes, and indivdual strips were probed with MAbs
MRPrl, MRPm6 andQCRL-1 (4 ng ml-) that had been preincubated for
45 min withthe indicated peptides. (A) Competiton of MAbs MRPm6 and
QCRL-1 binding with increasing concentrabons of peptide PSDLLQQRGL
(0-200 ng mt-). (B) compettion of MAbs MRPrl andQCRL-1 binding with
increasing concentrabons ofpeptide GSDLWSLNKE (0-100 gg mt-). (C)
Topological model of MRP depicting theapproximate locations of the MRPrI.
MRPm6 andQCRL-1 epitopes. The model shown is only one of several
possibleconfigurations (Hipfner etal. 1997). MSD. membrane spanning
domain: NBD. nucleotide binding domain
Sf-1 insect cells that had been infected with recombinant
baculovirus expressing two different human MRP constructswvith
deletions in the region against which this MAbwas raised. These
deletion constructs. Sf2l/MRP}l1 and Sf2I/MRP, ,. encode
MRP molecules lacking the amino terminal 228 and 280 amino
acids respectively. Duplicate dot blots of membranes prepared
from SfCU/MRP , ,- or Sf_l/MRP, infected cells were
probed with MAb MRPrl and MRP-1 polyclonal antiserum. As
expected. the MRP-1 antiserum reacted %-ith both the MRP.1,;1
and MRP,, membrane fractions (Figure 1. top) as this anti-
serum was raised against a peptide in the first NBD ofMRP whose
sequence is present in both deletion constructs. In contrast. MAb
MRPr l reacted with MRP, 11,, membranes but not w ith
MRP,, membranes (Figure 1. bottom). These results indicate
that the epitope for this MAb was not present in the
Sf Il/MRP,, construct and therefore must be located between
amino acids 229 and 280.
Localization of the MAb MRPm6 epitope
We have previously reported that formic acid hvdrolysis ofMRP is
predicted to yield nine fragments ranging in size from 13 to 376
amino acids (Hipfner et al. 1996) (Figure 2). The MRP sequence
against wvhich MAb MRPm6 was raised (amino acids 1294-1430
and 1497-1531 ) contains formic acid cleasage sites at amino acids
1376 and 1389. To deterrmine the approximate location ofthe MAb
MRPm6 epitope. we investigated the possibility that its epitope
miaht be located in one of three formic acid fraaments of this
region. Tsv-o of the three fragments are large enough to be resolxved
by electrophoresis on Tris-Tricine gels. One is a COOH-terminal
fragment composed of amino acids 1390-1531 (142 amino acids
with a predicted molecular mass of 15.9 kDa) and the other is an
internal fragment composed of amino acids 1003-1376 (374
amino acids w-ith a predicted molecular mass of 41.7 kDa).
Duplicate blots of MRP-enriched H69AR membranes hydrolysed
with formic acid were prepared after SDS-polyacrylamide gel
electrophoresis (PAGE) on Tris-Tricine gels. One blotwas probed
with MRP-2. a polyclonal antiserum that recognizes a sequence
(amino acids 1427-1441) predicted to be in the carboxy-terminal
formic acid fragment. This antiserum detected a doublet of MRP
formic acid fragments of molecular mass 14-16 kDa (Figure 2.
left). consistent with the expected sizes of the 142 amino acid
carboxy-terrminal fragment and a larger 155 amino acid frarment
(MRP amino acids 1377-1531) resulting from incomplete hydrol-
ssis. The second blotwas probed with MAb MRPm6.which also
reacted with two fragments of the same size (Fioure 2.right). In
view ofthe fact that the polypeptide used as an immunogen lacked
MRP amino acids 1431-1496. these results indicated that the
MRPm6 epitopewas located between amino acids 1390 and 1430
orbetween 1497 and 1531.
Epitope mapping with overlapping peptides
Blots of immobilized overlapping peptides encompassing regions
of MRP shown to contain the epitopes recognized by MAbs
MRPrl and MRPm6 were prepared and probedw-ith the appro-
priate MAb. Eleven decapeptides overlapping by fi e amino acids
and spanningy MRP amino acids 228-287 w-ere synthesized on a
membrane and probed with MAb MRPrl. This antibody showed
strong reactivity with the peptide GSDLWSLNKE corresponding
toamino acids 238-247 of MRP (Figrure 3A). Forty-fixe decapep-
tides and one nonapeptide overlapping by seven residues and
spanningr MRP amino acids 1388-1531 A-ere synthesized on a
membrane and probed with MAb MRPm6. This antibodv showed
strong reactivity with the peptide PSDLLQQRGL correspondin,
toamino acids 1511-1520 near the carboxy terminus of MRP
(Figure 3B).
Free forms of the peptides GSDLWSLNKE and PSDL-
LQQRGL were used in a competitive immunoassay to confirm the
specificity of the interactions observed in the blots of immobilized
peptides. Immunoblots of membrane proteins from MRP-trans-
fected cells were probed with MAbs MRPm6. MRPrl and QCRL-
1 alone or in the presence of increasing concentrations of free
peptide. Peptide GSDLWSLNKE inhibited the binding of MAb
MRPrl to MRP in a concentration-dependent manner. and almost
completely inhibited binding inthis assay at a concentration of
40 ng ml-' (Figure 4A). In contrast. the binding of MAb QCRL-1
Akas not affected by this peptide at the highest concentration tested
(200 ng ml-' ) indicatinr that theinteraction betsween MAb MRPrl
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Figure 5 Alignment of the amino acid sequences of the MRP epitopes for
MAbs MRPm6 and MRPrI with comparable regions in several known MRP-
related mammalian ABC proteins. (A) Epitope sequence of MAb MRPri. (B)
Epitope sequence of MAb MRPm6. The sequences of MRP-3, 4, and 5 are
not numbered because their complete cDNA sequences have not yet been
reported. MRP-6 does not contain a sequence comparable with the MRPrl
epitope. Identical amino acids are shaded. Sequences were obtained from
the EMBUGenBank Data Libraries using the following accession numbers:
human MRP, L05628; murine mrp, AF022908; human MOAT. U492428; rat
moat, L49379; rabbit EBCR, Z49144; human SUR1, L78207; human CFTR,
M28668; MRP3, U83659; MRP4, U83660; MRP5, U83661; MRP6, U91318
and peptide GSDLWSLNKE is specific. Similarly. peptide PSDL-
LQQRGL inhibited the binding of MAb MRPm6 to MRP in a
concentration-dependent manner but had no effect on the binding
ofMAb QCRL-1 at the highest concentration tested (100 j.t ml-')
(Fioure 4B). indicating, that the interaction betwxeen MAb MRPm6
and peptide PSDLLQQRGL is specific. The locations of the
MRPm6. MRPrl and QCRL-1 epitopes in the MRP molecule are
shown in Fig. 4C.
DISCUSSION
MRP is a relatixely newly described multidrug resistance protein
that. in mammalian cells. confers a phenotype similar to that asso-
ciated with overexpression ofP-glycoprotein. at least with respect
to the classes of drugs to wxhich it confers resistance (Loe et al.
1996a: Deeley and Cole. 1997). Consequently. there is consider-
able interest in determining the relexance of MRP in clinical drug
resistance. Sexeral studies examining the expression of MRP in
clinical specimens using MRP-reactix-e MAbs suggcest that MRP
may be important in a variety of human tumours (Nooter et al.
1995: Filipits et al. 1996a. b: Flens et al. 1996: Chan et al. 1997).
In addition to being essential for studies in clinical samples. MRP-
reactive MAbs have also been extremel useful in structure-func-
tion analyses and topological studies of MRP (Bakos et al. 1996:
Gao et al. 1996: Hipfner et al. 1996. 1997: Loe et al. 1996b.c and
1997). It may be anticipated that. analogous to MAbs for other
ABC proteins (Shapiro and Ling. 1994: O Riordan et al. 1995:
Illina et al. 1997). they will also prove useful for purification and
reconstitution studies of MRP. Given their pivotal role in both
clinical and experimental investigations of MRP. it is important
that these immunoreagents are well characterized.
With the exception of antisera raised against peptide sequences
in the relatixely highly conserxved NBDs of MRP. none of the
MRP-reactive antisera or MAbs currently available have been
demonstrated to cross-react with P-glycoprotein. This obserxation
is not surprising in view of the very low sequence identity (<15%)
between these two proteins. More recently. however. several ABC
transporters with substantially greater similarity to MRP than P-
glycoprotein have been cloned and characterized. For example. the
amino acid sequence ofthe multispecific orgarnic anion transporter
(MOAT) is approximately 50% identical to that of MRP
(Paulusma et al. 1996: Taniguchi et al. 1996). and the recently
published partial sequences for human MRP3. MRP4 and MRP5
suggest the existence of mammalian ABC proteins with exen
greater sequence similarity (Kool et al. 1997). Thus. as the ABC
superfamily expands and the number of MRP-related proteins
increases correspondinaly. the specificity of the MRP-reactive
MAbs becomes less certain. Concems about cross-reactixvity can
be greatly aHleviated by knowing the epitope sequence recognized
by a given MAb. which allows direct sequence comparisons. For
example. we have previously determiined that the sequence of the
QCRL-1 epitope is not found in any other ABC protein character-
ized to date (Hipfner et al. 1996). Indeed. even though the amino
acid sequence of murine mrp is 88%c identical to that of human
MRP. the QCRL-1 heptapeptide epitope is not conserved in the
murine sequence. consistent with the lack of cross-reactivity of
this MAb with the murine protein (Hipfner et al. 1996: Stride et al.
1996). Thus. knowledge ofthe QCRL-I epitope sequence provides
assurance that this MAb is a highly specific probe for human MRP
and makes it possible to use free peptide to compete for antibody
binding in various immunoassays.
An alignment of the amino acid sequences of the MRPrl and
MRPm6 epitopes in human MRP with the comparable regions in
several MRP-related mammalian ABC proteins shows that. with
the exception of murine mrp. these epitope sequences are poorly
conserved (Figure 5). The murine mrp sequence corresponding to
the human MRPrl epitope differs by only one amino acid. a
findinc consistent with the reported cross-reactivity of MAb
MRPrl with murine mrp (Figure 5A) (Flens et al. 1994: Lorico et
al. 1996). In view of the low conservation of the MAb MRPrl
epitope in other known MRP-related proteins. it is reasonable to
conclude that this MAb is specific for MRP/mrp. The MRPm6
epitope is also highly conserved in the murine mrp sequence and
differs by only two amino acids (Asp'"' -) Glu''l': Leul'-+'
Ile'"l) (Figure SB). These differences are verx conserxative and.
consequently. would not necessarily be expected to alter substan-
tiallv recognition by MAb MRPm6. Therefore. it is somewhat
surprising, that this MAb has been reported not to cross-react w-ith
murine mrp. a findingx we have confirmed by dot-blot analysis of
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mrp-enriched membranes (data not shown). These observations,
together with the low level conservation of the epitope sequence
among other known MRP-related ABC transporters (Figure 5B),
indicate that MAb MRPm6 may be considered a human MRP-
specific probe at present.
In conclusion, the data shown in the present study together with
those of our previous investigations demonstrate that MAbs
MRPrl, MRPm6 and QCRL-1 recognize highly specific linear
epitopes of MRP and, further, that MAbs MRnPm6 and QCRL-1
are specific probes for the human protein. Because each of the
three epitopes is in a different region of MRP, these reagents will
continue to be extremely valuable tools for both clinical and
structure-function analyses of this protein. We have previously
described three additional MAbs, namely, MAbs QCRL-2, QCRL-
3 and QCRL-4, which detect different confonnation-dependent
intracellular epitopes in the MRP molecule (Hipfner et al, 1994).
We have also determined that all three of these MAbs are capable
of inhibiting the transport function of MRP when measured
in inside-out membrane vesicles (Loe et al, 1996b, c, 1997).
Accordingly, studies are in progress to map the epitope sequences
of these MAbs because they are expected to provide important
information about the sites and mechanism(s) ofsubstrate binding
and transport by MRP.
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